Whole body 18FDG-PET/MRI as compared with 18FDG-PET/CT in metastatic breast cancer
Amy Melsaether 1 , Akshat C. Pujara 2 , Kristine Pysarenko 2 , Roy A. Raad 2 , Fabio Ponzo 2 , Kent Friedman 2 , Hersh Chandarana 2 , Komal Jhaveri 2 , Eric Sigmund 2 , Sungheon Kim 2 , and Linda Moy 2
NYU, New York, New York, United
New York, United States
In this prospective disease-specific study of 50
breast cancer patients, 18FDG-PET/MRI detected
potentially treatment changing brain, liver and
bone metastases not seen on PET/CT in 8 (16%) or
patients and PET/CT occult in situ breast
cancers in 5 (10%). Average 18FDG-PET/MRI
radiation dose was 50% that of 18FDG-PET/CT.
This abstract and the presentation materials are available to members only;
a login is required.